Qlaris Bio Revenue and Competitors
Estimated Revenue & Valuation
- Qlaris Bio's estimated annual revenue is currently $1.7M per year.
- Qlaris Bio's estimated revenue per employee is $155,000
Employee Data
- Qlaris Bio has 11 Employees.
- Qlaris Bio grew their employee count by 0% last year.
Qlaris Bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Qlaris Bio?
At Qlaris, our lead program is QLS-101, a novel topical ocular therapy that lowers intraocular pressure with a unique mechanism of action. QLS-101 is distinct from currently available therapies by lowering episcleral venous pressure (EVP) and improving outflow distal to the trabecular meshwork. This novel mechanism may enable the treatment of diseases where options remain limited, such as Normal Tension Glaucoma or Sturge-Weber Syndrome, and also provide an additive therapeutic option for patients requiring further efficacy for Primary Open Angle Glaucoma or in combination with Minimally-Invasive Glaucoma Surgery devices.
keywords:N/A
N/A
Total Funding
11
Number of Employees
$1.7M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Wellesley
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.5M | 12 | N/A | N/A |
#2 | $3.5M | 12 | -14% | N/A |
#3 | $2.2M | 15 | -46% | N/A |
#4 | $2.6M | 16 | 7% | N/A |
#5 | $1.7M | 20 | -29% | N/A |